Chronic granulomatous disease - conventional treatment vs. hematopoietic stem cell transplantation: an update

Area of Science:

• Immunology
• Hematology
• Pediatric Medicine

Background:

• Chronic granulomatous disease (CGD) is a primary immunodeficiency disorder.
• Advances in azole antifungal therapy have improved survival rates in CGD patients.
• Long-term survival in CGD has led to an increased recognition of inflammatory complications.

Purpose of the Study:

• To review recent advancements in conventional treatments for CGD.
• To summarize current findings on hematopoietic stem cell transplantation (HSCT) for CGD.
• To define optimal timing for HSCT in CGD management.

Main Methods:

• Literature review of recent studies on CGD treatment.
• Analysis of outcomes for conventional therapies.
• Evaluation of HSCT efficacy, including reduced-intensity conditioning.

Main Results:

• Azole antifungals have significantly improved survival in CGD.
• Inflammatory complications are increasingly prevalent with improved survival.
• HSCT demonstrates excellent outcomes in severe CGD, even with reduced-intensity conditioning.

Conclusions:

• HSCT is the preferred treatment for severe CGD when a donor is available.
• Early HSCT is recommended to prevent severe sequelae from infections and inflammation.
• This approach optimizes long-term health outcomes for CGD patients.